Agents and Actions

, Volume 12, Issue 5, pp 700–701 | Cite as

Platelet-activating factor (PAF-acether): Historical background and definition

  • J. Benveniste
Platelets and Thrombosis


The platelet-activating factor (PAF-acether) was first described as released from sensitized basophils. It is now recognized as a mediator of inflammation, since it is released from most stimulated pro-inflammatory cells. It has a unique phospholipid structure and, as yet, is the most potent platelet-activating agent acting at the 1×10−12 to 1×10−10M level. It also degranulates and attracts neutrophils. Its release from alveolar macrophages might play a role in the onset of bronchoconstriction in experimental animals and in man. Thus, PAF-acether is gaining increasing importance as a major intermediate of inflammatory reactions.


Experimental Animal Inflammatory Reaction Alveolar Macrophage Historical Background Major Intermediate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. [1]
    J.F. Barbaro andN.J. Zvaifler, Proc. Soc. exp. Biol. Med.122, 1245–1247 (1966).PubMedGoogle Scholar
  2. [2]
    R.P. Siraganian andA.G. Osler, J. Immun.106, 1244–1251 (1971).PubMedGoogle Scholar
  3. [3]
    J. Benveniste, P.M. Henson andC.G. Cochrane, J. exp. Med.136, 1356–1377 (1972).Google Scholar
  4. [4]
    J. Benveniste, Nature, Lond.249, 581–582 (1974).Google Scholar
  5. [5]
    J. Benveniste, J.P., Le Couedic andP. Kamoun, LancetI, 344 (1975).CrossRefGoogle Scholar
  6. [6]
    M.C. O'Donnell, P.M. Henson andB.A. Fiedel, Immunology35, 953–958.Google Scholar
  7. [7]
    J. Benveniste, J.P. Le Couedic, J. Polonsky andM. Tence, Nature, Lond.269, 170–171 (1977).Google Scholar
  8. [8]
    C.A. Demopoulos, R.N. Pinckard andD.J. Hanahan, J. biol. Chem.354, 9355–9358 (1979).Google Scholar
  9. [9]
    J. Benveniste, M. Tence, P. Varenne, J. Bidault, C. Boullet andJ. Polonsky, C. r. hebd. Séanc. Acad. Sci., Paris289D, 1037–1040 (1979).Google Scholar
  10. [10]
    J.J. Goldfroid, F. Heymans, E. Michel, H.C. Redeuilh, E. Steiner andJ. Benveniste, FEBS Lett.116, 161–164 (1980).CrossRefPubMedGoogle Scholar
  11. [11]
    F. Heymans, E. Michel, M.C. Borrel, B. Wichrowski, J.J. Godfroid, O. Convert, E. Coeffier, M. Tencé andJ. Benveniste, Biochim. biophys. Acta666, 230–237 (1981).PubMedGoogle Scholar
  12. [12]
    D.J. Hanahan, C.A. Demopoulos, J. Liehr andR.N. Pinckard, J. biol. Chem.255, 5514–5516 (1980).PubMedGoogle Scholar
  13. [13]
    E.J. Goetzl, C.K. Derian, A.I. Tauber andF.H. Valone, Biochem. biophys. Res. Commun.94, 881–888 (1980).CrossRefPubMedGoogle Scholar
  14. [14]
    M. Tence, E. Coeffier, F. Heymans, J. Polonsky, J.J. Godfroid andJ. Benveniste, Biochimie63, 723–727 (1981).PubMedGoogle Scholar
  15. [15]
    G. Camussi, C. Tetta, F. Bussolino, F. Caligaris Cappio, R. Coda, C. Masera andG. Segoloni, Int. Archs Allergy appl Immun.64, 24–41 (1981).Google Scholar
  16. [16]
    J.T. O'Flaherty, R.L. Wykle, C.H. Miller, J.C. Lewis, M. Waite, A. Bass, C.E. McCall andL.R. Dechatelet, Am. J. Pathol.103, 70–79 (1981).PubMedGoogle Scholar
  17. [17]
    E. Jouvin-Marche, B. Poitevin andJ. Benveniste, Agents and Actions, this issue.Google Scholar
  18. [18]
    B.B. Vargafitg, J. Lefort, M. Chignard andJ. Benveniste, Eur. J. Pharmac.65, 185–192 (1980).CrossRefGoogle Scholar

Copyright information

© Birkhäuser Verlag 1982

Authors and Affiliations

  • J. Benveniste
    • 1
  1. 1.INSERM U 200ClamartFrance

Personalised recommendations